Nutrition & metabolism · Topeka, KS
Nutrition and metabolism studies in Topeka, KS
9 recruiting studies have a site in Topeka.
9 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Topeka, KS + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Topeka, KS + 112 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Topeka, KS + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim
- Location
- Topeka, KS + 154 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc
- Location
- Topeka, KS + 130 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company
- Location
- Topeka, KS + 136 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
GlaxoSmithKline
- Location
- Topeka, KS + 46 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
GlaxoSmithKline
- Location
- Topeka, KS + 28 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
GlaxoSmithKline
- Location
- Topeka, KS + 62 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Expect limits on supplements, alcohol and diet changes during the study, and sometimes a set BMI range.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.